Research summary
Research HubCJC-1295
Clinical — 10 studies
CJC-1295 is a synthetic growth hormone–releasing hormone (GHRH) analogue studied for its ability to stimulate endogenous growth hormone secretion.
Being studied for
- Endogenous growth hormone stimulation
- IGF-1 modulation
Published Research
Evidence profile
Controlled human evidence
10 cited publications · 2 primary trials
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL et al. · The Journal of clinical endocrinology and metabolism · 2006
The study reportedSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M et al. · The Journal of clinical endocrinology and metabolism · 2006
The study reportedCJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I.
Additional indexed literature (8)
- Review · ReviewNetnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
Van Hout MC et al. · Substance use & misuse · 2016 · PMID 26771670
- Preclinical · Mechanistic studyAdvances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh S et al. · Drug testing and analysis · 2021 · PMID 34665524
- Preclinical · Mechanistic studyA method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS
Timms M et al. · Drug testing and analysis · 2019 · PMID 30938069
- Preclinical · Mechanistic studyAn immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
Timms M et al. · Drug testing and analysis · 2019 · PMID 30489688
- Preclinical · Mechanistic studyIdentification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation
Henninge J et al. · Drug testing and analysis · 2010 · PMID 21204297
- Preclinical · Mechanistic studyActivation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Sackmann-Sala L et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009 · PMID 19386527
- Preclinical · Mechanistic studyOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Alba M et al. · American journal of physiology. Endocrinology and metabolism · 2006 · PMID 16822960
- Preclinical · Pharmacokinetic studyHuman growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Jetté L et al. · Endocrinology · 2005 · PMID 15817669
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.